Association of Antibodies to Interferon-Inducible Protein-16 with Markers of More Severe Disease in Primary Sjögren's Syndrome

Arthritis Care and Research

Volumn 68, Issue 2, 2016, Pages 254-260

  Baer, Alan N ^a   Petri, Michelle ^a   Sohn, Jungsan ^a   Rosen, Antony ^a   Casciola Rosen, Livia ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; CYTOKINE; EPITOPE; INTERFERON INDUCIBLE PROTEIN 16; INTERFERON INDUCIBLE PROTEIN 16 ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; IFI16 PROTEIN, HUMAN; NUCLEAR PROTEIN; PHOSPHOPROTEIN;

ADOLESCENT; AMINO TERMINAL SEQUENCE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CELL LYSATE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GERMINAL CENTER; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SALIVARY GLAND; SCHIRMER TEST; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; ADULT; AGED; BLOOD; CASE CONTROL STUDY; IMMUNOLOGY; METABOLISM; MIDDLE AGED;

ADULT; AGED; BIOMARKERS; CASE-CONTROL STUDIES; EPITOPES; FEMALE; HUMANS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PHENOTYPE; PHOSPHOPROTEINS; SALIVARY GLANDS; SJOGREN'S SYNDROME;

EID: 84957111372     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22632     Document Type: Article

References (23)

1. Morrone SR, Wang T, Constantoulakis LM, Hooy RM, Delannoy MJ, Sohn J., Cooperative assembly of IFI16 filaments on dsDNA provides insights into host defense strategy. Proc Natl Acad Sci U S A 2014; 111: E62-71.
2. Mondini M, Costa S, Sponza S, Gugliesi F, Gariglio M, Landolfo S., The interferon-inducible HIN-200 gene family in apoptosis and inflammation: implication for autoimmunity. Autoimmunity 2010; 43: 226-31.
3. Seelig HP, Ehrfeld H, Renz M., Interferon-γ-inducible protein p16: a new target of antinuclear antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1994; 37: 1672-83.
4. Mondini M, Vidali M, de Andrea M, Azzimonti B, Airo P, D'Ambrosio R, et al., A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16. Arthritis Rheum 2006; 54: 3939-44.
5. Uchida K, Akita Y, Matsuo K, Fujiwara S, Nakagawa A, Kazaoka Y, et al., Identification of specific autoantigens in Sjögren's syndrome by SEREX. Immunology 2005; 116: 53-63.
6. Caneparo V, Cena T, de Andrea M, Dell'oste V, Stratta P, Quaglia M, et al., Anti-IFI16 antibodies and their relation to disease characteristics in systemic lupus erythematosus. Lupus 2013; 22: 607-13.
7. Costa S, Borgogna C, Mondini M, de Andrea M, Meroni PL, Berti E, et al., Redistribution of the nuclear protein IFI16 into the cytoplasm of ultraviolet B-exposed keratinocytes as a mechanism of autoantigen processing. Br J Dermatol 2011; 164: 282-90.
8. Costa S, Mondini M, Caneparo V, Afeltra A, Airo P, Bellisai F, et al., Detection of anti-IFI16 antibodies by ELISA: clinical and serological associations in systemic sclerosis. Rheumatology (Oxford) 2011; 50: 674-81.
9. Daniels TE, Criswell LA, Shiboski C, Shiboski S, Lanfranchi H, Dong Y, et al., An early view of the international Sjögren's syndrome registry. Arthritis Rheum 2009; 61: 711-4.
10. Shiboski SC, Shiboski CH, Criswell L, Baer A, Challacombe S, Lanfranchi H, et al., American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 2012; 64: 475-87.
11. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al., The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
12. Hochberg MC., Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
13. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-40.
14. Bloch KJ, Buchanan WW, Wohl MJ, Bunim JJ., Sjögren's syndrome: a clinical, pathological, and serological study of sixty-two cases. Medicine (Baltimore) 1965; 44: 187-231.
15. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al., Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-8.
16. Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L., The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 2011; 65: 25-34.
17. Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL, et al., Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum 2013; 65: 2954-62.
18. Casciola-Rosen L, Nagaraju K, Plotz P, Wang K, Levine S, Gabrielson E, et al., Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005; 201: 591-601.
19. Whitcher JP, Shiboski CH, Shiboski SC, Heidenreich AM, Kitagawa K, Zhang S, et al., A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjögren's Syndrome International Registry. Am J Ophthalmol 2010; 149: 405-15.
20. Manoussakis MN, Georgopoulou C, Zintzaras E, Spyropoulou M, Stavropoulou A, Skopouli FN, et al., Sjögren's syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjögren's syndrome. Arthritis Rheum 2004; 50: 882-91.
21. Pan HF, Ye DQ, Wang Q, Li WX, Zhang N, Li XP, et al., Clinical and laboratory profiles of systemic lupus erythematosus associated with Sjögren syndrome in China: a study of 542 patients. Clin Rheumatol 2008; 27: 339-43.
22. Nossent JC, Swaak AJ., Systemic lupus erythematosus VII: frequency and impact of secondary Sjögren's syndrome. Lupus 1998; 7: 231-4.
23. Jonsson H, Nived O, Sturfelt G, Norberg R., Symptomatic secondary Sjögren's syndrome in patients with systemic lupus erythematosus (SLE): relation to anti-SS-A and anti-SS-B autoantibodies. Scand J Rheumatol Suppl 1986; 61: 166-9.